Dual Inhibition of Mitochondrial Matrix Chaperones and Anti-Apoptotic Bcl-2 Family Members for Glioblastoma Therapy.
Dual Inhibition of Mitochondrial Matrix Chaperones and Anti-Apoptotic Bcl-2 Family Members for Glioblastoma Therapy.
批准号:
9754260
负责人:
MARKUS D SIEGELIN
金额:
$35.0万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-08-01 至 2021-07-31
关键词:
AdultAnimal ModelApoptosisApoptoticAutophagocytosisBCL2 geneBiological ModelsBrain NeoplasmsCell DeathCellsClinical TrialsCombined Modality TherapyDataDevelopmentDiagnosisDiseaseDrug CombinationsFamily memberGeldanamycinGeneticGlioblastomaGliomaGoalsHematologic NeoplasmsHeterogeneityIn VitroInner mitochondrial membraneLife ExpectancyMCL1 geneMalignant neoplasm of brainMediatingMembraneMitochondriaMitochondrial MatrixMolecular ChaperonesMusNeoplasmsNormal CellOralOuter Mitochondrial MembranePathway interactionsPatientsPharmacologyPharmacotherapyPopulationPrimary Brain NeoplasmsProtein FamilyProteinsReagentResearchResearch PersonnelResistanceSolid NeoplasmTP53 geneTestingTherapeuticTimeToxic effectTransgenic OrganismsTreatment EfficacyTreatment ProtocolsUnited StatesWorkXenograft ModelXenograft procedureactivating transcription factor 4antitumor effectapoptosis deregulationclinical developmentcombatcytotoxiceffective therapyexpectationfactor Afallsimprovedin vitro Modelin vivoin vivo Modelindividualized medicineinhibitor/antagonistinnovationmalignant breast neoplasmmelanomamimeticsneoplastic cellnoveloutcome forecastpatient stratificationpublic health relevancereceptorside effectstem-like celltherapy resistanttreatment strategytumortumor growthtumor heterogeneitytumor xenograftvirtual
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary:
Glioblastoma multiforme is the most common primary brain tumor with about 8500 cases
diagnosed each year in the United States. Within a time frame of 15 month virtually all
patients succumb to this detrimental disease despite treatment efforts. Therefore, novel,
ideally tumor specific approaches are necessary to combat these tumors. While single
reagents may efficiently target other tumors, such as hematological malignancies,
Glioblastoma is strikingly different since it is a tumor that is characterized by extensive
heterogeneity, demanding the simultaneous inhibition of ideally several deregulated
pathways. Our previous research has shown that targeting mitochondrial matrix
chaperones displays significant anti-glioma effects. In this proposal, an accomplished
team of investigators will be characterizing a novel treatment concept for glioblastoma by
dual targeting of two deregulated pathways in tumor mitochondria. In the first specific
aim we will test this novel treatment concept, utilizing several in vitro model systems of
glioblastoma with a special focus on so called stem cell-like glioma cells, a population of
tumor cells that drive therapeutic resistance in these neoplasms. Our preliminary data
indicate that our treatment concept efficiently targets this pivotal cell population. In order
to further improve our treatment concept we will study the cell death mechanisms
involved in the combination treatment. In the second aim, we will characterize the
mechanisms that are involved in this treatment approach, which is a centerpiece of our
proposal and may further allow us to better understand and tailor treatments and
potentially to stratify patients that in particular may benefit from this treatment approach.
In the third specific aim we will test this treatment concept in current in vivo model
systems of glioblastoma, which will extend our preliminary data that suggest that this
treatment concept is active in vivo. Overall, this research may enhance our
understanding about the treatment of brain tumors and may potentially allow us to
formulate a novel treatment strategy for glioblastoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HDAC inhibitors reverse the Warburg Effect and Elicit Metabolic Vulnerabilities in Model Systems of Glioblastoma
-
批准号:10376222
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2021
-
负责人:MARKUS D SIEGELIN
-
依托单位:
HDAC inhibitors reverse the Warburg Effect and Elicit Metabolic Vulnerabilities in Model Systems of Glioblastoma
-
批准号:10649574
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2021
-
负责人:MARKUS D SIEGELIN
-
依托单位:
HDAC inhibitors reverse the Warburg Effect and Elicit Metabolic Vulnerabilities in Model Systems of Glioblastoma
-
批准号:10209026
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2021
-
负责人:MARKUS D SIEGELIN
-
依托单位:
Targeting Mutant IDH1 for a Novel Synthetic Lethal Interaction in Malignant Gliomas
-
批准号:10363698
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2018
-
负责人:MARKUS D SIEGELIN
-
依托单位:
Targeting Mutant IDH1 for a Novel Synthetic Lethal Interaction in Malignant Gliomas
-
批准号:9891109
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2018
-
负责人:MARKUS D SIEGELIN
-
依托单位:
Targeting Mutant IDH1 for a Novel Synthetic Lethal Interaction in Malignant Gliomas
-
批准号:10116496
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2018
-
负责人:MARKUS D SIEGELIN
-
依托单位:
Dual Inhibition of Mitochondrial Matrix Chaperones and Anti-Apoptotic Bcl-2 Family Members for Glioblastoma Therapy.
-
批准号:9190880
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2016
-
负责人:MARKUS D SIEGELIN
-
依托单位:
Overcoming apoptotic resistance in glioblastoma by CP-d/n-ATF5, a novel tumor spe
-
批准号:8756885
-
项目类别:
-
资助金额:$18.74万
-
财政年份:2014
-
负责人:MARKUS D SIEGELIN
-
依托单位:
Overcoming apoptotic resistance in glioblastoma by CP-d/n-ATF5, a novel tumor spe
-
批准号:9096229
-
项目类别:
-
资助金额:$18.74万
-
财政年份:2014
-
负责人:MARKUS D SIEGELIN
-
依托单位:
Overcoming apoptotic resistance in glioblastoma by CP-d/n-ATF5, a novel tumor spe
-
批准号:8899651
-
项目类别:
-
资助金额:$18.74万
-
财政年份:2014
-
负责人:MARKUS D SIEGELIN
-
依托单位:
海外基金